| Pharmaceuticals and Biotechnology | Novel antibiotics, biosimilar insulins, respiratory and anti-infective drugs. | Strong IP portfolio, global manufacturing, QIDP designations, and regulatory approvals. | Healthcare providers, hospitals, and patients worldwide (B2B and B2C). | Novel antibiotics and biosimilar insulins with strong patent protection. | 2504 | 83 | Product sales in global pharmaceutical markets and licensing revenues. | Sales-based revenue with market-driven pricing, plus licensing agreements. | R&D innovation, regulatory approvals, and expanding global product portfolio. | Zaynich, Miqnaf, Emrok, Wosulin, Glaritus, Aspart insulin products |
| Super Specialty Hospitals | Specialty hospital services and healthcare delivery in India. | Established brand with quality hospital infrastructure and clinical expertise. | Patients in India seeking specialized medical care (B2C). | Specialty care and advanced surgical services. | 512 | 17 | Fee-for-service healthcare revenue model. | Service-based fees, insurance billings, and outpatient consults. | Healthcare demand in India, expansion of hospital network and services. | Advanced multispecialty hospitals under Wockhardt brand |
